Diamedica Therapeutics Inc (DMAC) Stock Price, Quote & News

Company Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human...

Industry: Biotechnology

Sector: Healthcare

Phone: 763 496 5454

Website: www.diamedica.com

Address:

301 Carlson Parkway, Suite 210, Minneapolis, United States

MedCred Mar. 19 at 3:31 PM

$DMAC Now with 56 sites in US, Canada, and Europe. New update from Clinical trials.gov

1 · Reply

Relee187200 Mar. 17 at 2:56 PM

$DMAC Very weak given that articles are good! Any thoughts on why and any catalyst coming?

0 · Reply

MedCred Mar. 15 at 4:34 PM

$DMAC https://www.newsbytesapp.com/news/science/new-drug-shows-potential-in-treating-life-threatening-pregnancy-complication/story

0 · Reply

DARKP00L Mar. 5 at 1:26 PM

$DMAC 07:38 on Mar. 05 2026 DiaMedica Therapeutics Gets No Objection Letter From Health Canada For Its Clinical Study Application Of DM199 In Phase 2 Trial In Participants With Early-Onset Preeclampsia #tradeideas

1 · Reply

OfficialStocktwitsUser Feb. 20 at 1:58 PM

$DMAC RSI: 50.45, MACD: 0.0842 Vol: 0.29, MA20: 8.35, MA50: 8.39 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

oaksapollo Feb. 18 at 2:24 AM

$DMAC I really like this approach to pre-eclampsia, but the stroke opportunity seems a bit risky and likely to create more problems/delays. Thoughts?

1 · Reply

Sicksir Feb. 17 at 3:22 AM

$DMAC https://www.npr.org/2026/02/14/nx-s1-5708744/preeclampsia-pregnancy-complication-treatment

0 · Reply

BillionerOfKing Feb. 16 at 7:34 PM

$DMAC Current Stock Price: $8.53 Contracts to trade: $7.5 DMAC Feb 20 2026 Call Entry: $0.30 Exit: $0.52 ROI: 75% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

TalkMarkets Feb. 6 at 2:01 PM

#DiaMedica Therapeutics Strengthens Balance Sheet with $12.2 Million Capital Raise While Advancing Preeclampsia Program $DMAC https://talkmarkets.com/content/stocks--equities/diamedica-therapeutics-strengthens-balance-sheet-with-122-million-capital-raise-while-advancing-preeclampsia-program?post=555510&userid=166882

0 · Reply

codename41 Feb. 3 at 6:35 PM

$DMAC 🍸

0 · Reply

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

Feb 24, 2026, 9:23 AM EST - 25 days ago

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

Jan 16, 2026, 5:00 PM EST - 2 months ago

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 18, 2025, 8:45 AM EST - 3 months ago

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

Nov 13, 2025, 10:01 AM EST - 4 months ago

DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:30 PM EST - 4 months ago

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 10, 2025, 8:15 AM EST - 4 months ago

DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 4:15 PM EST - 4 months ago

DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

Sep 29, 2025, 4:15 PM EDT - 6 months ago

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Sep 5, 2025, 8:30 AM EDT - 7 months ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

Sep 2, 2025, 8:23 AM EDT - 7 months ago

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

Aug 13, 2025, 3:58 PM EDT - 7 months ago

DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia

Aug 13, 2025, 11:36 AM EDT - 7 months ago

DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:15 PM EDT - 7 months ago

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 6, 2025, 8:00 AM EDT - 8 months ago

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

Aug 5, 2025, 4:15 PM EDT - 8 months ago

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

Jul 23, 2025, 4:30 PM EDT - 8 months ago

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

Jul 21, 2025, 8:00 AM EDT - 8 months ago

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

Jul 17, 2025, 8:00 AM EDT - 8 months ago

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

Jun 24, 2025, 8:30 AM EDT - 9 months ago

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

May 22, 2025, 8:30 AM EDT - 10 months ago

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

May 19, 2025, 9:00 AM EDT - 10 months ago

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

May 14, 2025, 4:30 PM EDT - 11 months ago

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

May 14, 2025, 11:05 AM EDT - 11 months ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:30 PM EDT - 11 months ago

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

May 8, 2025, 4:00 PM EDT - 11 months ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

May 7, 2025, 8:30 AM EDT - 11 months ago

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

Mar 18, 2025, 10:27 AM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

Mar 11, 2025, 8:23 AM EDT - 1 year ago

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

Feb 24, 2025, 8:30 AM EST - 1 year ago

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

Feb 20, 2025, 8:15 AM EST - 1 year ago

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

Feb 10, 2025, 4:15 PM EST - 1 year ago

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 3, 2024, 8:25 AM EST - 1 year ago

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

Nov 14, 2024, 12:49 PM EST - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:20 PM EST - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:05 PM EST - 1 year ago

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Nov 12, 2024, 8:23 AM EST - 1 year ago

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

Nov 6, 2024, 8:32 AM EST - 1 year ago

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

Oct 9, 2024, 8:27 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Sep 4, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Upcoming Conference Participation

Aug 7, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

Aug 1, 2024, 8:20 AM EDT - 1 year ago

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

Jul 11, 2024, 2:48 PM EDT - 1 year ago

DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point

Jul 11, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

Jul 1, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

Jun 26, 2024, 8:15 AM EDT - 1 year ago

DiaMedica Therapeutics Announces $11.8 Million Private Placement

Jun 26, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

May 11, 2024, 4:49 PM EDT - 2 years ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:30 PM EDT - 2 years ago

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

MedCred Mar. 19 at 3:31 PM

$DMAC Now with 56 sites in US, Canada, and Europe. New update from Clinical trials.gov

1 · Reply

Relee187200 Mar. 17 at 2:56 PM

$DMAC Very weak given that articles are good! Any thoughts on why and any catalyst coming?

0 · Reply

MedCred Mar. 15 at 4:34 PM

$DMAC https://www.newsbytesapp.com/news/science/new-drug-shows-potential-in-treating-life-threatening-pregnancy-complication/story

0 · Reply

DARKP00L Mar. 5 at 1:26 PM

1 · Reply

OfficialStocktwitsUser Feb. 20 at 1:58 PM

0 · Reply

oaksapollo Feb. 18 at 2:24 AM

$DMAC I really like this approach to pre-eclampsia, but the stroke opportunity seems a bit risky and likely to create more problems/delays. Thoughts?

1 · Reply

Sicksir Feb. 17 at 3:22 AM

$DMAC https://www.npr.org/2026/02/14/nx-s1-5708744/preeclampsia-pregnancy-complication-treatment

0 · Reply

BillionerOfKing Feb. 16 at 7:34 PM

0 · Reply

TalkMarkets Feb. 6 at 2:01 PM

0 · Reply

codename41 Feb. 3 at 6:35 PM

$DMAC 🍸

0 · Reply

codename41 Feb. 2 at 9:25 PM

$DMAC loaded

0 · Reply

Biohub Jan. 28 at 12:31 PM

$DMAC I follow Leon Cooperman, he owns DMAC and his picks have been outstanding. Hold this company and forget it, you’ll be glad you dud.

0 · Reply

carlosrromero26 Jan. 23 at 12:38 AM

$DMAC @Pegger cantor Fitzgerald held a call yesterday with the lead doctor doing the research on DM 199 to treat preeclampsia and she used the word magical to describe what she had witnessed after giving a patient the drug. “Dr. Cluver was very enthusiastic about her experience dosing patients with DM199. She recalls watching blood pressure lower within 5-10 minutes in these patients with severe, refractory hypertension - “it feels a bit like magic”

1 · Reply

Pegger Jan. 22 at 4:37 PM

$DMAC the silence is deafening

1 · Reply

Northerner2 Jan. 6 at 1:18 AM

$DMAC On December 19, 2025 DiaMedica Therapeutics Inc. (the “Company”) Sold 1,501,000 common shares to a healthcare institution fund at a purchase price of $8.10 per share in a block transaction under its at-the-market offering program. The Company received $12.2 million in gross proceeds, before deducting fees and other expenses payable by it.

0 · Reply

Northerner2 Jan. 6 at 1:18 AM

$DMAC 8-K filing today - On December 19, 2025 DiaMedica Therapeutics Inc. (the “Company”) Sold 1,501,000 common shares to a healthcare institution fund at a purchase price of $8.10 per share in a block transaction under its at-the-market offering program. The Company received $12.2 million in gross proceeds, before deducting fees and other expenses payable by it.

0 · Reply

OfficialStocktwitsUser Jan. 6 at 12:17 AM

$DMAC RSI: 36.42, MACD: 0.0712 Vol: 0.45, MA20: 8.57, MA50: 7.71 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

justiceforb_85 Jan. 5 at 9:03 PM

$DMAC data from RCT of REMEDY1 published. Bit concerning that even when taking out patients who underwent EVT there was no difference or strong signal in rinvecalinase group. Anyone with additional data which may be more reassuring for AIS? https://journals.sagepub.com/doi/10.1177/17474930251396480?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

1 · Reply

RealAvidTrader Dec. 18 at 3:29 PM

$DMAC Is This Stock Setting Up For An Epic Squeeze? (All Time High Short Interest) https://youtu.be/VNC3IaXDP-M

0 · Reply

Thestocktraderhubzee Dec. 18 at 2:53 PM

$DMAC DiaMedica Therapeutics Completes Productive In-Person Pre-IND Meeting With FDA For Planned Study Evaluating DM199 In Preeclampsia

0 · Reply

Sicksir Dec. 18 at 2:06 PM

$DMAC MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced completion of a productive in-person pre-IND meeting with the United States Food and Drug Administration (FDA) for a planned study evaluating DM199 in preeclampsia. Minutes from the meeting affirmed the FDA’s request for one additional non-clinical, 10-day modified embryo-fetal development (EFD) and pre- and postnatal development (PPND) study in a rabbit model. Preparations for this study have commenced, and results are expected to be available by the second quarter of 2026.

1 · Reply

Market Cap	352.04M
Revenue (ttm)	0.00
Net Income (ttm)	-24.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	285,700
Avg Vol	212,222
Day's Range	N/A - N/A
Shares Out	52.08M
Stochastic %K	6%
Beta	1.09
Analysts	Strong Sell
Price Target	$15.50